Wegovy weight loss by dose: separating fact from expectation

The myth worth letting go: that the first pen tells you how well it will work

A lot of people start Wegovy at 0.25mg, notice relatively little change in appetite or weight in the first four weeks, and quietly worry the medicine is not working for them. It is a very understandable concern. But the 0.25mg starting dose is not designed to produce significant weight loss, its job is to reduce the chance of nausea and other gastrointestinal side effects as your system adapts to semaglutide. Judging Wegovy's effect at this stage is a bit like assessing a car's performance in first gear on a quiet road.

The same logic applies through the 0.5mg step. Both early doses exist for tolerability, and most people move through them without any dramatic change on the scales. This is not a sign of treatment failure. It is the schedule working as intended. The detail page on 0.5mg Wegovy and weight loss explains what that phase typically looks like in practice. Gentle and patient at the start is exactly right; the evidence for weight loss builds at the higher therapeutic doses.

Clinical trials enrolled participants who completed the full titration and stayed on treatment for over a year. Results reported in those papers reflect that entire journey, not a snapshot at week four. If you are currently on a lower dose and feeling uncertain, that is a conversation worth having with your prescriber rather than a reason to stop.

What the dose-specific evidence shows from 1mg upwards

From 1mg onwards, most people begin to notice a more consistent reduction in appetite and, over time, in body weight. The 1mg phase is still a transitional step in the maintenance schedule, but it tends to be where the appetite-suppressing effect of semaglutide becomes more noticeable day to day. The prescriber moves patients through this step based on how well the previous dose was tolerated, not on how much weight has been lost so far.

At 1.7mg, weight reduction typically continues to build. By the time patients reach the 2.4mg maintenance dose, the STEP 1 trial reported an average body weight reduction of around 15% over 68 weeks compared with placebo. That figure (cited by NICE in their semaglutide appraisal (TA875)) covers the whole population studied, so individual results both above and below that average were common. Some people lost considerably more; some less. Weight, health history, diet, activity and how consistently the medicine was taken all play a role.

The 2.4mg maintenance dose is where most people on the standard Wegovy schedule have historically stayed. The full breakdown of how results develop at that level is covered in the 2.4mg Wegovy weight loss page, including what the trial data shows about the pace of loss over time. Loss is rarely linear, it tends to be faster early on and slower after the first few months.

The 7.2mg dose: what the newer evidence adds

In April 2026, the MHRA approved a dedicated single-dose 7.2mg Wegovy pen (one weekly injection) for adults with a BMI of 30 or above. This was a significant development. Trial data showed approximately 20.7% average weight loss over 72 weeks at this dose, which narrows the gap considerably with tirzepatide results at higher doses. The starting dose remains 0.25mg, titrated by the prescriber over several months; 7.2mg is the ceiling, not the starting point.

Whether the 7.2mg option is appropriate for a given patient is a clinical judgement. Dose availability is confirmed during the consultation rather than assumed in advance. If you want to understand the full picture of how the Wegovy dose schedule is structured before speaking to a prescriber, the Wegovy doses guide covers the titration pathway in detail.

It is also worth noting that what looks like a modest dose difference on paper can represent a meaningful change in how the medicine behaves. Semaglutide's effect is dose-dependent, higher doses produce greater GLP-1 receptor activation, slower gastric emptying, and stronger appetite suppression. That is why the schedule exists, and why rushing through it tends not to work in anyone's favour.

Putting dose-related weight loss in context before you start

The numbers from clinical trials are a useful reference, but they sit alongside a lot of individual variation. A 15% reduction in body weight represents a substantial health benefit for most people living with obesity, the kind that can improve blood pressure, blood sugar, joint load and cardiovascular risk in meaningful ways. The full Wegovy overview covers the wider evidence base if you want more background on how those health outcomes are measured.

Understanding the cost involved is also part of making an informed decision. The Wegovy prices page sets out what private treatment typically involves and what a transparent service price should include.

If you are weighing Wegovy against other treatment options, the weight-loss treatment overview is a good starting point for comparison. And if you have questions a page cannot fully answer, our prescribers are available through the free consultation, a real clinician reads your answers the same day, not software working through a queue.